☰

cached image

Alan P. Kozikowski

Affiliations: 
University of Illinois at Chicago, Chicago, IL, United States 
Area:
medicinal chemistry
Website:
http://foto.pharm.uic.edu/mcp/people/kozikowski_ap.html
Google:
"Alan Kozikowski"
Bio:

Alan P. Kozikowski was born in 1948 in Menominee, MI. He received his Ph.D. degree from the University of California, Berkeley, under the supervision of the late Professor W. G. Dauben. After postdoctoral work with Professor E. J. Corey at Harvard University, Dr. Kozikowski began his independent career at the University of Pittsburgh. After 14 years there, he spent 3 years at the Mayo Clinic and then moved on to the Georgetown University Medical Center, where he is the Director of the Drug Discovery Program. Dr. Kozikowski's interests are in the areas of drug abuse, medications development, second messenger based therapeutics for cancer, and novel chemical interventions for the treatment of Alzheimer's disease.

Mean distance: 7.15
 		SNBCP
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
William G. Dauben grad student 1974 UC Berkeley
 (Studies related to the synthesis of sesquiterpenes)
Elias James Corey post-doc 1974-1976 Harvard

Children

Sign in to add trainee
Arun K. Ghosh grad student 1985 University of Pittsburgh
Jay Kalin grad student 2012 University of Illinois, Chicago
Michael J Malaska post-doc 1991-1993 Mayo Cllinic Jacksonville
Dawei Ma post-doc 1990-1994 University of Pittsburgh and the Mayo Clinic
Jia Zhou post-doc 2001-2003
Marinella Roberti research scientist Mayo Clinic

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Huang J, Wang L, Dahiya S, et al. (2017) Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function. Scientific Reports. 7: 8626
Ugolkov A, Qiang W, Bondarenko G, et al. (2017) Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. Translational Oncology. 10: 669-678
Zhang G, Cheng J, McCorvy JD, et al. (2017) Discovery of N-Substituted 2-Phenylcyclopropylmethylamines as Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists for Potential Use as Antipsychotic Medications. Journal of Medicinal Chemistry
Lv W, Zhang G, Barinka C, et al. (2017) Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors. Acs Medicinal Chemistry Letters. 8: 510-515
Pogorelov VM, Rodriguiz RM, Cheng J, et al. (2017) 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Budke B, Lv W, Tueckmantel W, et al. (2017) Abstract PR02: Small molecules that specifically inhibit the D-loop activity of RAD51 Molecular Cancer Research. 15
Kim J, Nair JR, Hadley MM, et al. (2017) Abstract LB-295: A novel regulatory role of HDAC6 in the functional inflammatory phenotype of glia cells Cancer Research. 77
Hadley M, Shen S, Banik D, et al. (2017) Abstract LB-294:In vivoevaluation of Ames negative HDAC6 inhibitor in melanoma model Cancer Research. 77
Banik D, Hadley M, Kim J, et al. (2017) Abstract 4854: Evaluating HDAC6 as a causal factor in metastatic breast cancer to develop immunotherapy Cancer Research. 77: 4854-4854
Damião MCFCB, Galaverna R, Kozikowski AP, et al. (2017) Telescoped continuous flow generation of a library of highly substituted 3-thio-1,2,4-triazoles Reaction Chemistry and Engineering. 2: 896-907
See more...